PAR2 induces ovarian cancer cell motility by merging three signalling pathways to transactivate EGFR

Specific cellular functions mediated by GPCRs are often associated with signalling through a particular G protein or β‐arrestin. Here, we examine signalling through a GPCR, protease‐activated receptor 2 (PAR2), in a high‐grade serous ovarian cancer cell line (OV90).

• Publication year

  2020

• Venue

  British Journal of Pharmacology

• Publication date

  2020-11-23

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/bph.15332PMID 33226635
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Visualizing and interpreting cancer genomics data via the Xena platform

  2020cited by this paper
• Protease-activated receptor signalling initiates α5β1-integrin-mediated adhesion in non-haematopoietic cells

  2020cited by this paper
• GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis

  2019cited by this paper
• THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein‐coupled receptors

  2019cited by this paper
• Proteinase-activated receptor 2 promotes tumor cell proliferation and metastasis by inducing epithelial-mesenchymal transition and predicts poor prognosis in hepatocellular carcinoma

  2018cited by this paper
• Goals and practicalities of immunoblotting and immunohistochemistry: A guide for submission to the British Journal of Pharmacology

  2018cited by this paper
• A Potent Antagonist of Protease-Activated Receptor 2 That Inhibits Multiple Signaling Functions in Human Cancer Cells

  2018cited by this paper
• Positive crosstalk between EGFR and the TF-PAR2 pathway mediates resistance to cisplatin and poor survival in cervical cancer

  2018cited by this paper
• Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

  2018cited by this paper
• Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers

  2018cited by this paper
• In situ click chemistry generation of cyclooxygenase-2 inhibitors

  2017cited by this paper
• Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)

  2017cited by this paper
• Biased Signaling by Agonists of Protease Activated Receptor 2.

  2017cited by this paper
• The ovarian cancer oncobiome

  2017cited by this paper
• Distinct conformations of GPCR–β-arrestin complexes mediate desensitization, signaling, and endocytosis

  2017cited by this paper
• A pathology atlas of the human cancer transcriptome

  2017influential reference
• Emerging functions of the EGFR in cancer

  2017cited by this paper
• Expression of protease-activated receptor-2 (PAR-2) is related to advanced clinical stage and adverse prognosis in ovarian clear cell carcinoma.

  2017cited by this paper
• Gαi is required for carvedilol-induced β1 adrenergic receptor β-arrestin biased signaling

  2017cited by this paper
• Tissue factor-factor VIIa complex triggers protease activated receptor 2-dependent growth factor release and migration in ovarian cancer.

  2017cited by this paper
• GPCR-G Protein-β-Arrestin Super-Complex Mediates Sustained G Protein Signaling.

  2016cited by this paper
• Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours

  2015cited by this paper
• Epidermal Growth Factor Receptor Is Critical For Angiotensin II–Mediated Hypertrophy in Cerebral Arterioles

  2015cited by this paper
• Transactivation of epidermal growth factor receptor through platelet-activating factor/receptor in ovarian cancer cells

  2014cited by this paper
• Genetic modifiers of EGFR dependence in non-small cell lung cancer

  2014cited by this paper
• Gαs regulates the post-endocytic sorting of G protein-coupled receptors

  2014cited by this paper
• Diet‐induced obesity, adipose inflammation, and metabolic dysfunction correlating with PAR2 expression are attenuated by PAR2 antagonism

  2013cited by this paper
• Diet-induced obesity , adipose inflammation , and metabolic dysfunction correlating with PAR 2 expression are attenuated by PAR 2 antagonism

  2013cited by this paper
• Metastasis of ovarian cancer is mediated by kallikrein related peptidases

  2013cited by this paper
• Paclitaxel Resistance and Multicellular Spheroid Formation Are Induced by Kallikrein-Related Peptidase 4 in Serous Ovarian Cancer Cells in an Ascites Mimicking Microenvironment

  2013cited by this paper
• SurvExpress: An Online Biomarker Validation Tool and Database for Cancer Gene Expression Data Using Survival Analysis

  2013cited by this paper
• Noncanonical GPCR signaling arising from a PTH receptor–arrestin–Gβγ complex

  2013cited by this paper
• Protease‐activated receptor‐2 induces migration of pancreatic cancer cells in an extracellular ATP‐dependent manner

  2013cited by this paper
• Deciphering biased-agonism complexity reveals a new active AT1 receptor entity.

  2012influential reference
• Profiling of cytokines in human epithelial ovarian cancer ascites.

  2012cited by this paper
• Tissue factor-PAR2 signaling promotes diet-induced obesity and adipose inflammation

  2011cited by this paper
• Structure, function and pathophysiology of protease activated receptors.

  2011cited by this paper
• Tissue Factor-Factor VIIa Complex Induces Epithelial Ovarian Cancer Cell Invasion and Metastasis Through a Monocytes-Dependent Mechanism

  2011cited by this paper
• Faculty Opinions recommendation of Tissue factor-protease-activated receptor 2 signaling promotes diet-induced obesity and adipose inflammation.

  2011cited by this paper
• Cooperation of tissue factor cytoplasmic domain and PAR2 signaling in breast cancer development.

  2010cited by this paper
• PAR1 and PAR2 Couple to Overlapping and Distinct Sets of G Proteins and Linked Signaling Pathways to Differentially Regulate Cell Physiology

  2010cited by this paper
• Self-production of tissue factor-coagulation factor VII complex by ovarian cancer cells

  2009cited by this paper
• Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion

  2008cited by this paper
• NSAIDs and cancer prevention: targets downstream of COX-2.

  2007cited by this paper
• In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro

  2007cited by this paper
• Role of protease activated receptor-2 in tumor advancement of ovarian cancers.

  2007cited by this paper
• β-Arrestin–mediated β1-adrenergic receptor transactivation of the EGFR confers cardioprotection

  2007cited by this paper
• Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection.

  2007cited by this paper
• Circulating interleukin-6 induces fever through a STAT3-linked activation of COX-2 in the brain.

  2006cited by this paper
• Protease-activated receptor-2 activation in gastric cancer cells promotes epidermal growth factor receptor trans-activation and proliferation.

  2006cited by this paper
• Activation of cancer cell migration and invasion by ectopic synthesis of coagulation factor VII.

  2006cited by this paper
• The membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostate cancer cells.

  2005cited by this paper
• Protease‐activated receptor‐2 regulates cell proliferation and enhances cyclooxygenase‐2 mRNA expression in human pancreatic cancer cells

  2005cited by this paper
• A soybean Kunitz trypsin inhibitor suppresses ovarian cancer cell invasion by blocking urokinase upregulation

  2004cited by this paper
• Transmembrane serine protease TADG-15 (ST14/Matriptase/MT-SP1): expression and prognostic value in ovarian cancer

  2004cited by this paper
• Activation of proteinase-activated receptor 1 promotes human colon cancer cell proliferation through epidermal growth factor receptor transactivation.

  2004cited by this paper
• Protease-activated Receptor 2 in Colon Cancer

  2004cited by this paper
• Galphaq-coupled receptor internalization specifically induced by Galphaq signaling. Regulation by EBP50.

  2003cited by this paper
• Gαq-coupled Receptor Internalization Specifically Induced by Gαq Signaling

  2003cited by this paper
• Possible role of matriptase in the diagnosis of ovarian cancer

  2003cited by this paper
• Proteinase-activated receptors in the nervous system

  2003cited by this paper
• Prostaglandin E(2) stimulates prostatic intraepithelial neoplasia cell growth through activation of the interleukin-6/GP130/STAT-3 signaling pathway.

  2002cited by this paper
• Protease-activated receptors

  2002cited by this paper

• Targeting F2R/PAR1 with ligand decorated lipid nanocarriers for enhanced drug delivery into ovarian cancer cells

  2026cites this paper
• EGFR-Mutant Lung Adenocarcinoma Cell-Derived Exosomal miR-651-5p Induces CD8+ T Cell Apoptosis via Downregulating BCL2 Expression

  2025cites this paper
• Bioinformatics and experimental insights into F2RL1 as a key biomarker in cervical cancer diagnosis and prognosis

  2025cites this paper
• Therapeutic Targeting in Ovarian Cancer: Nano-Enhanced CRISPR/Cas9 Gene Editing and Drug Combination Therapy

  2025cites this paper
• Nano-polymeric platinum activates PAR2 gene editing to suppress tumor metastasis.

  2025cites this paper
• Proinflammatory effects of factor Xa on human dental pulp cells.

  2025cites this paper
• GPCR signaling from endosome: mechanistic insights and therapeutic potentials.

  2025cites this paper
• The Function and Clinical Significance of TRPV2 in Human Colon Cancer

  2025cites this paper
• Unveiling the Anticancer Potential of Curcuma Caesia Roxb. Against Ovarian Cancer: An Indigenous Plant of Assam

  2025cites this paper
• Trypsin, chymotrypsin and elastase in health and disease

  2024cites this paper
• Dual-functional Nanosized Albumin Facilitates CRISPR-Cas9-PAR2 to Mitigate Cytokine Storm via TLR4 and Pyroptosis Signaling.

  2024cites this paper
• Protease activated receptor 2 as a novel druggable target for the treatment of metabolic dysfunction-associated fatty liver disease and cancer

  2024cites this paper
• Melitoxin Inhibits Proliferation, Metastasis, and Invasion of Glioma U251 Cells by Down-regulating F2RL1

  2024cites this paper
• Involvement of Protease-Activated Receptor2 Pleckstrin Homology Binding Domain in Ovarian Cancer: Expression in Fallopian Tubes and Drug Design

  2024cites this paper
• Protease-activated receptor 2: a promising therapeutic target for women's cancers.

  2024cites this paper
• A novel inhibitor of class IIa histone deacetylases attenuates collagen‐induced arthritis

  2024cites this paper
• Photonanozyme–Kras–ribosome combination treatment of non-small cell lung cancer after COVID-19

  2024cites this paper
• G protein‑mediated EGFR transactivation is a common mechanism through which the CXCL12 receptors, CXCR4 and CXCR7, control human cancer cell migration.

  2023cites this paper
• Ras-Related Protein Rab5a Regulates Complement C5a Receptor Trafficking, Chemotaxis, and Chemokine Secretion in Human Macrophages

  2023cites this paper
• Applications of CRISPR Cas-9 in Ovarian Cancer Research.

  2023cites this paper
• Interplay between G protein-coupled receptors and nanotechnology.

  2023cites this paper
• Genome editing of PAR2 through targeted delivery of CRISPR-Cas9 system for alleviating acute lung inflammation via ERK/NLRP3/IL-1β and NO/iNOS signalling

  2023cites this paper
• PAR2 deficiency tunes inflammatory microenvironment to magnify STING signalling for mitigating cancer metastasis via anionic CRISPR/Cas9 nanoparticles.

  2023cites this paper
• Protease-activated receptor 2 attenuates doxorubicin-induced apoptosis in colon cancer cells

  2023cites this paper
• Low-Dose Trypsin Accelerates Wound Healing via Protease-Activated Receptor 2.

  2023cites this paper
• New insight into the agonism of protease-activated receptors as an immunotherapeutic strategy

  2023cites this paper
• Neurokinin-1 receptor promotes non-small cell lung cancer progression through transactivation of EGFR

  2022cites this paper
• PAR2 promotes tumor-associated angiogenesis in lung adenocarcinoma through activating EGFR pathway.

  2022cites this paper
• Elevated expression of the membrane-anchored serine protease TMPRSS11E in NSCLC progression.

  2022cites this paper
• Using GPCRs as Molecular Beacons to Target Ovarian Cancer with Nanomedicines

  2022cites this paper
• Inhibition of Protease Activated Receptor 2 Attenuates HBx-Induced Inflammation and Mitochondria Oxidative Stress

  2022cites this paper
• A Study of Stability Indicating Development and Validation of a Method for Simultaneous Estimation of Brigatinib and Alectinib Using Reverse Phase Ultra Performance Liquid Chromatography in Active Pharmaceutical Ingredient Form

  2022influential citation
• The Yin‐Yang roles of protease‐activated receptors in inflammatory signalling and diseases

  2022cites this paper
• PAR2 Promoter Hypomethylation Regulates PAR2 Gene Expression and Promotes Lung Adenocarcinoma Cell Progression

  2021cites this paper
• High Pressure Liquid Chromatographic Method for the Determination of Mobocertinib in Pharmaceutical Dosage Form and Study of Its Degradation

  2021cites this paper
• PAR2 blockade reverses osimertinib resistance in non-small-cell lung cancer cells via attenuating ERK-mediated EMT and PD-L1 expression.

  2021cites this paper
• Mast Cells Mediate Inflammatory Injury and Aggravate Neurological Impairment in Experimental Subarachnoid Hemorrhage Through Microglial PAR-2 Pathway

  2021cites this paper
• Targeting PAR2 Overcomes Gefitinib Resistance in Non-Small-Cell Lung Cancer Cells Through Inhibition of EGFR Transactivation

  2021cites this paper